Table 1.

Characteristics of patients with previous IFIs who received weekly L-AmB as secondary prophylaxis at MD Anderson (2003–2009)

Patient	Underlying disease status1	Age (years) /sex	Prior IFI				Secondary prophylaxis		Second IFI			L-AmB–attributable side effect	Follow-up
			Organ involved	Pathogen	Diagnostic certainty2	Treatment (duration)3	Dose (mg/kg/weight)	Duration (days)	Organ involved	Pathogen	Diagnostic certainty2
1	MCL, complete remission	55/M	Lungs	Aspergillus niger, Rhizopus	Proven	L-AmB + Vori (6 weeks)	6.5	59	Lungs, sinus	Aspergillus species	Probable	Acute renal injury	Death because of IFI at 1 month
2	AML, complete remission	52/M	Lungs	Aspergillus glaucus	Probable	L-AmB + ANF (4 weeks)	5	16	Lungs	Aspergillus spp	-	Acute renal injury	Alive after 1 year
3	AML, refractory	44/M	Lungs	unknown	Possible	Caspo + Vori (6 weeks)	10	18	Lungs	unknown	Possible	no	Death because of AML at 1 year
4	CML, refractory	51/M	Lungs	unknown	Possible	L-AmB (2 weeks)	6.2	27	-	-	-	Acute renal injury	Death because of CML at 3 months
5	AML, refractory	55/M	Lungs	unknown	Possible	L-AmB + Caspo (4 weeks)	7.5	26	Lungs	unknown	Possible	no	Death because of AML at 3 months
6	AML, complete remission	60/F	Foot Lungs	Fusarium species	Proven	L-AmB + Caspo (5 weeks)	7.5	20	-	-	-	no	Alive after 3 months
7	ALL, relapsed	27/F	Sinus	Rhizopus	Proven	L-AmB + Vori (9 months)	5	128	Sinus	Candida krusei, Candida glabrata	Probable	Acute renal injury	Death because of ALL at 1 year
8	ALL, complete remission	72/F	Lungs	Aspergillus species	Proven	L-AmB + Caspo (7 weeks)	7.5	70	-	-	-	no	Death because of ALL at 3 years
9	ALL, complete remission	70/M	Lungs	Aspergillus fumigatus	Probable	L-AmB + Caspo (4 weeks)	5	42	-	-	-	no	Death because of ALL at 1 year
10	ALL, complete remission	49/M	Lungs Sinus	unknown	Possible	L-AmB + Caspo (4 weeks)	7.5	96	-	-	-	no	Alive at 3 years
11	BPL, relapsed	56/M	Lungs Skin	Mucor circineloides	Proven	L-AmB + Caspo (4 months)	5	49	-	-	-	no	Death because of ALL at 2 months
12	AML, relapsed	73/M	Lungs	unknown	Possible	L-AmB + Posa (5 weeks)	9	14	-	-	-	yes	Death because of AML at 5 months
13	AML, relapsed	57/F	Blood Skin	Candida tropicalis	Proven	Caspo + Vori (2 weeks)	9	29	Lungs Skin	Candida tropicalis	Proven	no	Death because of AML at 1 year
14	AML, complete remission	52/F	Mandible	Rhizopus	Proven	L-AmB (10 weeks)	5	14	-	-	-	Acute renal injury	Death because of AML at 3 years

¹MCL, mantle cell lymphoma; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphocytic leukemia; BPL, biphenotypic leukemia.

²European Organization for Research and Treatment of Cancer and Infectious Diseases Mycoses Study Group criteria.

³Vori, voriconazole; ANF, anidulafungin; Caspo, caspofungin; Posa, posaconazole.